“Up until now the treatment of this condition involved free water restriction and removal of inciting factors. Now a new drug - Tolvaptan promises to change it all.”

However, the article missed out the remaining post which in the end had my take on Tolvaptan - “The main problem with the drug is that once approved, most clinicians will prescribe it for for a very long time especially in patients prone to developing and remaining hyponatremic. Since the study duration was only for 30 days, many new side effects may appear when the drug is finally marketed.”

Also the article was written in context of describing an article published in New England Journal of medicine and not for drug promotion which the article failed to mention. I should also add that I have no relationship with any pharmaceutical company as the article later implies by writing:

“A recent survey reveals that 29% of blog authors have been approached by public relations professionals to endorse specific products, and 52% of them have written one post endorsing such products in their blog content.23 These endorsements are not advertise- ments that appear on the website; they are written into the blog narrative, often without any acknowledgement that they are paid promotions. Although we did find blogs that promoted health care products within their entries, we were unable to determine whether these were paid endorsements, because we found no disclosures indicating authors’ conflicts of interest.”

I pursue blogging because I have a passion for computers and technology and believe that we can help ourselves (physicians) as well as our patients to try to empower them with the latest knowledge in medicine that they can discuss with their physicians.